Skip to main content
Premium Trial:

Request an Annual Quote

Everist Genomics Gets CLIA OK

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Everist Genomics today said that it has received the US Clinical Laboratory Improvement Amendment certification required for it to launch its OncoDefender-CRC assay.

The Ann Arbor, Mich.-based firm plans to officially launch the test, which is a gene-based assay used in stage I and II colon cancer and stage I rectal cancer patients to assess the risk of recurrence following surgery, later this month.

"We expect that meeting the challenging certification guidelines enabling our clinical laboratory to perform high-complexity testing will give physicians and patients greater confidence when ordering the OncoDefender-CRC test," Prasad Sunkara, president and CEO of Everist Genomics, said in a statement.

The Scan

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.

Study Points to Benefits of Local Consolidative Therapy, Targeted Treatments in Cancer Care

In JCO Precision Oncology, researchers report that local consolidative therapy combined with molecularly targeted treatments could improve survival for some lung cancer patients.

Genetic Variants That Lower LDL Cholesterol Linked to Reduced Heart Disease Risk

Rare variants in two genes that lower LDL cholesterol are also associated with a decreased risk of coronary heart disease, according to a new JAMA Cardiology study.

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.